Zusammenfassung
Eine 58-jährige Patientin, jetzt einem Kreatinin von 4,5 mg/dl, einem Harnstoff von 150 mg/dl, Übelkeit und Erbrechen, einem Body Mas Index von 28, Blutdruck von 150/95 mm Hg, einem LDL von 180 mg/dl, einer Makroalbuminurie und einem HbA1c von 8,0 %. Wie kann man die Dialyse hinauszögern?
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
ACCORD Study Group, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 362(17):1575–1585. https://doi.org/10.1056/NEJMoa1001286
ACCORD Study Group (2014) Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2(10):793–800. https://doi.org/10.1016/S2213-8587(14)70155-X
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, Investigators S (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, Investigators RS (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 345(12):861–869. https://doi.org/10.1056/NEJMoa011161
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New Engl J Med 329(20):1456–1462. https://doi.org/10.1056/nejm199311113292004
The DCCT/EDIC Research Group, Boer IH de, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New Engl J Med 365(25):2366–2376. https://doi.org/10.1056/NEJMoa1111732
Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German D, Dialysis Study I (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med 353(3):238–248. https://doi.org/10.1056/nejmoa043545
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kihm, L. (2018). Fall 20: Spätschäden – 58 Jahre, ♀, DM Typ 1, drohende Dialyse. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-662-55972-7_20
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55971-0
Online ISBN: 978-3-662-55972-7
eBook Packages: Medicine (German Language)